- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05798117
Un estudio abierto para evaluar la seguridad, la eficacia y la cinética celular de YTB323 en trastornos autoinmunitarios graves refractarios
Un estudio abierto, multicéntrico, de fase 1/2 para evaluar la seguridad, la eficacia y la cinética celular de YTB323 en participantes con trastornos autoinmunitarios graves refractarios
The study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Mainz, Alemania, 55131
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Alemania, 79106
- Novartis Investigative Site
-
-
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Novartis Investigative Site
-
-
-
-
-
Barcelona, España, 08035
- Novartis Investigative Site
-
Madrid, España, 28009
- Novartis Investigative Site
-
-
-
-
-
Paris, Francia, 75013
- Novartis Investigative Site
-
Pessac, Francia, 33604
- Novartis Investigative Site
-
Strasbourg, Francia, 67091
- Novartis Investigative Site
-
-
-
-
-
Bern, Suiza, 3010
- Novartis Investigative Site
-
Lausanne, Suiza, 1011
- Novartis Investigative Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed informed consent
- Adequate renal, hepatic, cardiac, hematological and pulmonary function
- Men and women with SLE, aged ≥18 years and ≤65 years at screening, fulfilling the 2019 European League Against Rheumatism EULAR/ACR classification criteria for SLE.
- Patient must be positive for at least one of the following autoantibodies at screening: antinuclear antibodies (ANA) at a titer of ≥1:80, or anti dsDNA (above the ULN); or anti-Sm (above the ULN)
- Active (severe) disease as defined by SLEDAI-2K ≥ 8 (not including the SLEDAI-2K domains of lupus headache, cerebrovascular accident, organic brain syndrome) and at least one of the following significant SLE related organ involvements:
- Renal
- At least moderate or severe peri/myocarditis
- At least moderate or severe pleuritis or other lung involvement
- Vasculitis
- Failure to respond to two or more standard immunosuppressive therapies (including one of mycophenolate or cyclophosphamide), unless contraindicated or having experienced documented adverse events or intolerance related to such immunosuppressive drugs not allowing their further use, in combination with glucocorticoids and failure to respond to at least one biological agent (unless contraindicated, the patient deemed ineligible by the Investigator or not available in a country).
Exclusion Criteria:
- Clinically significant active, opportunistic, chronic or recurrent infection confirmed by clinical evidence, imaging, or positive laboratory tests (e.g., blood cultures, PCR for DNA/RNA, such as COVID-19 etc.) one month prior to or during screening. Patients who have had at least one severe infection that required prolonged hospitalization in the intensive care setting within 5 years prior to screening and/or at least one severe infection that required prolonged hospitalization within one year prior to screening.
- Uncontrolled diabetes mellitus, lung diseases or any other illness that are not related to SLE that in the opinion of the Investigator would jeopardize the ability of the patient to tolerate lymphodepletion and CD19 CAR-T cell therapy
- Prior history of malignancy except for localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis
- Any patients requiring medications prohibited by the protocol
- Any psychiatric condition or disability making compliance with treatment or informed consent impossible
- Prior treatment with anti-CD19 therapy, adoptive T cell therapy or any prior gene therapy product (e.g. CAR-T cell therapy)
- History of bone marrow/hematopoietic stem cell or solid organ transplantation
- Female participants who are pregnant or breastfeeding, or intending to conceive during the course of the study
- Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a highly effective method of contraception starting from the time of enrollment to at least 12 months after the YTB323 infusion (or longer if required as per local regulations) and until CAR-T cells are no longer present by qPCR on two consecutive tests
- Sexually active males unwilling to use a condom during intercourse from the time enrollment for at least 12 months after the YTB323 infusion and until CAR-T cells are no longer present by qPCR on two consecutive tests
- Any acute, severe lupus related flare during screening that needs immediate treatment and/or makes the immunosuppressive washout impossible; thus, makes the patient ineligible for CD19 CAR-T therapy as judged by the Investigator, such as acute central nervous system (CNS) lupus (e.g. psychosis, epilepsy) or catastrophic antiphospholipid syndrome
- Significant, likely irreversible organ damage related to SLE, e.g. end stage renal disease, that in the opinion of the Investigator renders CD19 CAR-T cell therapy would be unlikely to benefit the patient
- B cell aplasia
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: YTB323
Single infusion of YTB323 |
Single infusion of YTB323 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants with AEs and SAEs
Periodo de tiempo: Day 1 to 2 years
|
Long term safety follow up |
Day 1 to 2 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Maximum observed blood concentration Cmax)
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to assess cellular kinetics. |
Pre-dose, up to 2 years
|
|
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Area under plasma concentration -time AUC)
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to assess cellular kinetics. |
Pre-dose, up to 2 years
|
|
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach maximum concentration Tmax)
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to assess cellular kinetics. |
Pre-dose, up to 2 years
|
|
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Terminal elimination half-life T1/2)
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to assess cellular kinetics. |
Pre-dose, up to 2 years
|
|
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Last measurable concentration Clast)
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to assess cellular kinetics. |
Pre-dose, up to 2 years
|
|
CAR transgene levels by quantitative polymerase chain reaction (qPCR) in blood (Time to reach last measurable concentration Tlast)
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to assess cellular kinetics. |
Pre-dose, up to 2 years
|
|
Number of patients with anti-drug antibodies
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to measure anti-drug antibodies against YTB323. |
Pre-dose, up to 2 years
|
|
Level of T cell activation by YTB323
Periodo de tiempo: Pre-dose, up to 2 years
|
Blood samples will be collected to measure the level of T cell activation by YTB323. |
Pre-dose, up to 2 years
|
|
Number of patients infused with planned target dose
Periodo de tiempo: Day 1
|
Feasibility of the manufacturing process in autoimmune disorders. |
Day 1
|
|
Change from pre-dose up to 2 years in the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score
Periodo de tiempo: Pre-dose, up to 2 years
|
SLEDAI-2K scores are between 0 and 105, a higher score represents a higher disease activity. |
Pre-dose, up to 2 years
|
|
Change from pre-dose up to 2 years in Physician's global assessment (PGA)
Periodo de tiempo: Pre-dose, up to 2 years
|
The Physician's Global assessment is a visual analog scale from 0 to 3, 0 represents no activity and 3 represents severe disease activity. |
Pre-dose, up to 2 years
|
|
Change from pre-dose up to 2 years in Lupus Low Disease Activity State (LLDAS)
Periodo de tiempo: Pre-dose, up to 2 years
|
LLDAS is a composite measure based on: SLEDAI-2K ≤ 4, with no activity in major organ system (renal, central nervous system, cardiopulmonary, vasculitis, and fever) and no hemolytic anemia or gastrointestinal activity, current, no new lupus disease activity compared with the previous assessment, prednisone (or its equivalent) dose ≤ 7.5 mg/day, PGA (scale 0-3) ≤ 1, well tolerated standard maintenance doses of immunosuppressive lupus therapy. |
Pre-dose, up to 2 years
|
|
Remission rate
Periodo de tiempo: Up to 2 years
|
Remission as specified by Definitions Of Remission In Systemic Lupus Erythematosus (DORIS) criteria: Clinical SLEDAI=0, PGA<0.5 (0-3) irrespective of serology. The patient may be on antimalarials, low-dose glucocorticoids (prednisolone ≤5 mg/day), and/or stable immunosuppressive therapy including biologics. |
Up to 2 years
|
|
Change from pre-dose up to 2 years in Urinary protein creatinine ratio (UPCR)
Periodo de tiempo: Pre-dose, up to 2 years
|
Change in the value of UPCR. |
Pre-dose, up to 2 years
|
|
Incidence of Complete renal response (CRR)
Periodo de tiempo: Up to 2 years
|
Number of participants who achieved CRR. |
Up to 2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Novartis Pharmaceuticals, Novartis Pharmaceutical
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Enfermedades del tejido conectivo
- Enfermedades autoinmunes
- Enfermedades del sistema inmunológico
- Glomerulonefritis
- Nefritis
- Enfermedades de la piel y del tejido conectivo
- Lupus Eritematoso Sistémico
- Nefritis lúpica
Otros números de identificación del estudio
- CYTB323G12101
- 2022-001796-14 (Número EudraCT)
- 2023 (Subvención/contrato del NIH de EE. UU.)
- 2023-510081-27-00 (Otro identificador: EU CT number)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .